Patents by Inventor Niall Martin
Niall Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210244706Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: ApplicationFiled: September 28, 2020Publication date: August 12, 2021Inventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Cameron Murray Smith
-
Publication number: 20170319543Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: ApplicationFiled: May 12, 2017Publication date: November 9, 2017Inventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Cameron Murray Smith
-
Publication number: 20120135983Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: ApplicationFiled: November 1, 2011Publication date: May 31, 2012Inventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith
-
Patent number: 8143241Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: GrantFiled: October 6, 2005Date of Patent: March 27, 2012Assignees: Kudos Pharmaceuticals Limited, The Institute of Cancer ResearchInventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith, Mark O'Connor
-
Patent number: 8071579Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: GrantFiled: November 30, 2004Date of Patent: December 6, 2011Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Kudos Pharmaceuticals LimitedInventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith
-
Publication number: 20080081809Abstract: There is provided a compound of formula I: , or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: ApplicationFiled: August 21, 2007Publication date: April 3, 2008Applicant: KuDOS Pharmaceuticals LimitedInventors: Heather Duggan, Karine Malagu, Frederic Leroux, Niall Martin, Keith Menear, Graeme Smith
-
Publication number: 20070238729Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.Type: ApplicationFiled: June 5, 2007Publication date: October 11, 2007Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Niall Martin, Graeme Smith, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Laurent Rigoreau, Xiao-ling Cockcroft, Vincent Junior Loh, Paul Workman, Florence Raynaud, Bernard Nutley
-
Publication number: 20070238731Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3 or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, oType: ApplicationFiled: September 20, 2005Publication date: October 11, 2007Applicants: KUDOS PHARMACEUTICALS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Graeme Smith, Niall Martin, Roger Griffin, Bernard Golding, Ian Hardcastle, Kappusamy Saravanan, David Newell, Hilary Calvert, Nicola Curtin, Keith Menear, Marc Hummersone
-
Publication number: 20070093489Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) ?where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) ?and where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C?O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2; RC1 and RC2 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; RC1 and RC2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C5Type: ApplicationFiled: October 17, 2006Publication date: April 26, 2007Applicant: KuDOS Pharmaceuticals LimitedInventors: Muhammad Javaid, Keith Menear, Sylvie Gomez, Marc Hummersone, Niall Martin, Graeme Smith, Xiao-Ling Cockcroft
-
Publication number: 20070049588Abstract: A compound of formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, and their use in treating diseases ameliorated by the inhibition of ATM.Type: ApplicationFiled: August 30, 2006Publication date: March 1, 2007Applicant: KuDOS Pharmaceuticals LimitedInventors: Graeme Smith, Niall Martin, Andrew Slade, Keith Menear, Marc Hummersone, Xiao-Ling Cockcroft, Ian Matthews, Laurent Rigoreau, Roger Griffin, David Newell, Nicola Curtin
-
Publication number: 20060264623Abstract: Compounds of formula l: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Marine Desage-El Murr
-
Publication number: 20060264427Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, HiIary Calvert, Nicola Curtin, Kappusamy Saravanan, Marine Desage-El Murr
-
Publication number: 20060178361Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms; and R3 is selected from hydroxy and —NRN1RN2, where RN1 and RN2 are independently selected from hydrogen, optionally substituted C1-7 alkyl groups, optionally substituted C3-20 heterocyclyl groups and optionally substituted C5-20 aryl groups, or together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms, and its use in inhibiting ATM.Type: ApplicationFiled: February 9, 2006Publication date: August 10, 2006Applicant: Kudos Pharmaceuticals LimitedInventors: Marc Hummersone, Keith Menear, Laurent Rigoreau, Graeme Smith, Niall Martin, Roger Griffin
-
Publication number: 20060149059Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.Type: ApplicationFiled: December 23, 2005Publication date: July 6, 2006Applicants: Kudos Pharmaceuticals Limited, Maybridge LimitedInventors: Niall Martin, Graeme Smith, Stephen Jackson, Vincent Loh, Xiao-Ling Cockcroft, Ian Matthews, Keith Menear, Frank Kerrigan, Alan Ashworth
-
Publication number: 20060142293Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; RC is represented by -L-RL, where L is of formula: —(CH2)n1-Qn2-(CH2)n3— wherein n1, n2 and n3 are each selected from 0, 1, 2 and 3, the sum of n1, n2 and n3 is 1, 2 or 3 and Q is selected from O, S, NH, C(?O) or —CR1R2—, where R1 and R2 are independently selected from hydrogen, halogen or optionally substituted C1-7 alkyl, or may together with the carbon atom to which they are attached form a C3-7 cyclic alkyl group, which may be saturated (a C3-7 cycloalkyl group) or unsaturated (a C3-7 cycloalkenyl group), or one of R1 and R2 may be attached to an atom in RL to form an unsaturated C3-7 cycloalkenyl group which comprises the carbon atoms to which R1 and R2 are aType: ApplicationFiled: February 10, 2006Publication date: June 29, 2006Applicants: Kudos Pharmaceuticals Limited, Maybridge plcInventors: Niall Martin, Graeme Smith, Charles White, Roger Newton, Diane Douglas, Penny Eversley, Julia Vile
-
Publication number: 20060142231Abstract: DNA Damage Repair Inhibitors for Treatment of Cancer The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: ApplicationFiled: October 6, 2005Publication date: June 29, 2006Inventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith, Mark O'Connor
-
Publication number: 20060135770Abstract: A compound of the formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; n is 1 or 2; RN1 and RN2 are independently selected from H and R, where R is optionally substituted C1-10 alkyl, C3-20 heterocyclyl and C5-20 aryl; or RN1 and RN2, together with the nitrogen atom to which they are attached form an optionally substituted 5-7 membered, nitrogen containing, heterocylic ring; Het is selected from: where Y1 and Y3 are independently selected from CH and N, Y2 is selected from CX and N and X is H, Cl or F; and where Q is O or S.Type: ApplicationFiled: December 22, 2005Publication date: June 22, 2006Applicant: Kudos Pharmaceuticals Ltd.Inventors: Muhammad Javaid, Graeme Smith, Niall Martin, Sylvie Gomez, Vincent Loh, Xiao-Ling Cockcroft, Keith Menear
-
Publication number: 20060106025Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl gType: ApplicationFiled: September 20, 2005Publication date: May 18, 2006Applicants: Kudos Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Laurent Rigoreau, Roger Griffin, Bernard Golding, David Newell, Hilary Calvert, Nicola Curtin, Ian Hardcastle, Kappusamy Saravanan
-
Publication number: 20050227919Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.Type: ApplicationFiled: November 30, 2004Publication date: October 13, 2005Inventors: Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith
-
Publication number: 20050107367Abstract: The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1 and R2 are independently hydrogen, an option ally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3 is an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,Type: ApplicationFiled: August 14, 2002Publication date: May 19, 2005Inventors: Niall Martin, Graeme Cameron Smith, Roger Griffin, Bernard Golding, Ian Hardcastle, Laurent Rigoreau, David Newell, Hilary Calvert, Nicola Curtin, Paul Workman, Florence Raynaud, Bernard Nutley